N/A N=70 Comparison Study of the ICON™ CPAP Series With and Without SensAwake™
Obstructive Sleep Apnea
Primary: Adherence to CPAP Treatment — 272.672; 289.087 mins
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=212 Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Primary: Progression Free Survival (PFS) — 4.3; 3.0; 4.2 Months — p=0.584
Phase 4 N=28 Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™
Herpes Zoster · Fibrosis
Primary: ELISPOT, Interferon-G Enzyme-Linked Immunospot Assay — 0; 0
Phase 3 N=835 A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Primary: Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks In Double Blind Period — 0.290; 0.155 relapses/participant year of…
Phase 3 N=821 A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Primary: Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks — 0.292; 0.156 relapses/participant year of treatment — p=<0.0001
Phase 4 N=128 Partnership for Rapid Elimination of Trachoma
Trachoma
Primary: Community Prevalence of Trachoma and Ocular C. Trachomatis (CT) Infection at Baseline — 30.7; 30.3; 31.1; 30.5 community
Phase 2 N=100 Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Multiple Myeloma · Lymphoma, Non-Hodgkin
Primary: Comparison of the Mean Day 5 CD34+Cells/kg Yield Between the Two Arms — 11.6; 10.0 cells/kg
Phase 2 N=41 A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Best Overall Response (BOR) in Participants With T790M Mutation — 0; 1; 7; 6 Participants
N/A N=44 Expression of Angiogenic Biomarkers During Healing of Intra-Oral Soft Tissue Engineered Grafts
Gingival Recession
Primary: Differences in Angiogenic Biomarkers — 0.51; .69; 1.04; .67 ng/mL
Phase 4 N=171 Attention Deficit Disorder Medication Response Study
ADHD - Inattentive Type · ADHD - Combined Type
Primary: Attention Deficit Hyperactivity Disorder Total Symptom Score — 21.4; 30.0; 20.2; 29.7 units on a scale — p=<0.05
Phase 2 N=138 Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant
Graft Versus Host Disease
Primary: Percentage of Participants With Incidence of Grade II-IV GVHD — 33; 31; 21 Percentage of participants
N/A N=2,777 Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement
Severe Aortic Stenosis
Primary: Extreme Risk: All-cause Death or Major Stroke; High Risk Surgical: All-cause Mortality — 22.5; 30.8; 17.8 percentage of participants, Kaplan-Meier
Phase 4 N=19 Use of Cidofovir for Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis
Primary: Change in Papilloma Severity — 13.2; 12; 3.7; 3.6 scores on a scale
Phase 2 N=594 Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women
HIV Infection
Primary: Occurrence of Grade 3 or Higher Adverse Events (AEs) — 18; 24; 20; 28 Participants
Phase 3 N=658 A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Progression-free Survival (PFS) — 7.4; 3.8 months — p=<0.0001